Neuroblastoma 2

Common Name(s)

Neuroblastoma 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroblastoma 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroblastoma 2" returned 147 free, full-text research articles on human participants. First 3 results:

Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
 

Author(s): Dan Li, Hong Mei, Jiarui Pu, Xuan Xiang, Xiang Zhao, Hongxia Qu, Kai Huang, Liduan Zheng, Qiangsong Tong

Journal:

 

Recent studies have revealed the potential roles of intelectin 1 (ITLN1) in tumorigenesis. However, its functions and underlying mechanisms in neuroblastoma (NB), the most common extracranial solid tumor in childhood, still remain largely unknown.

Last Updated: 19 Apr 2015

Go To URL
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2β) isoform contributes to neuroblastoma tumorigenesis.
 

Author(s): Angela Russo, Mustafa Nazir Okur, Maarten Bosland, John P O'Bryan

Journal: Cancer Lett.. 2015 Apr;359(2):262-8.

 

Phosphatidylinositol 3-kinases (PI3Ks) play important roles in human tumorigenesis. Activation of the PI3K target AKT is frequent in neuroblastoma (NB) and correlates with poor prognosis. PI3K pan-inhibitors reduce NB tumor formation but present severe toxicity, which limits their ...

Last Updated: 21 Feb 2015

Go To URL
Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
 

Author(s): Rachelle R Olsen, Michelle N Mary-Sinclair, Zhirong Yin, Kevin W Freeman

Journal:

 

Neuroblastomas (NBL) and Ewing's sarcomas (EWS) together cause 18% of all pediatric cancer deaths. Though there is growing interest in targeting the dysregulated metabolism of cancer as a therapeutic strategy, this approach has not been fully examined in NBL and EWS. In this study, ...

Last Updated: 24 Jan 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroblastoma 2" returned 1 free, full-text review articles on human participants. First 3 results:

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
 

Author(s): Brett H Yamane, Jacquelyn A Hank, Mark R Albertini, Paul M Sondel

Journal: Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000.

 

Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine hu14.18-IL2 (EMD-273063) was developed by means of fusion of two molecules of IL-2 to the monoclonal ...

Last Updated: 24 Jun 2009

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma; High-Risk

 

Last Updated: 26 Feb 2016

Go to URL
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
 

Status: Recruiting

Condition Summary: Neuroblastoma

 

Last Updated: 5 Jan 2016

Go to URL